Skip to main content

Table 3 Adjusted association of fibrinogen and Lp(a) categories with clinical outcomes

From: Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

Risk factor Tertile/range KM rates (%) Hazard ratio (95% CI) p value
Lp(a) categories Total     0.001
  Lp(a)-L (< 10) 3.5 Reference  
  Lp(a)-M (10–29.9) 5.3 1.531 1.128–2.079 0.006
  Lp(a)-H (≥ 30) 5.6 1.786 1.315–2.426  < 0.001
Fibrinogen categories Total     0.002
  Fib-L(< 2.84) 4.0 Reference  
  Fib-M(2.85–3.42) 4.4 1.001 0.726–1.379 0.996
  Fib-H(≥ 3.43) 6.1 1.558 1.162–2.089 0.003
Combined categories Total     0.002
  G1(Lp(a)-L + Fib-L) 3.3 Reference  
  G2(Lp(a)-L + Fib-M) 3.5 1.203 0.687–2.107 0.518
  G3(Lp(a)-L + Fib-H) 4.0 1.476 0.831–2.619 0.184
  G4(Lp(a)-M + Fib-L) 4.1 1.482 0.846–2.596 0.169
  G5(Lp(a)-M + Fib-M) 4.9 1.511 0.866–2.636 0.146
  G6(Lp(a)-M + Fib-H) 7.0 2.307 1.409–3.777 0.001
  G7(Lp(a)-H + Fib-L) 4.8 1.912 1.085–3.369 0.025
  G8(Lp(a)-H + Fib-M) 5.4 1.707 0.984–2.962 0.057
  G9(Lp(a)-H + Fib-H) 7.2 2.656 1.628–4.333  < 0.001
  1. Data are expressed as HR (95% CI). L low, M medium, H high. Covariates used for adjustment are age, sex, BMI, diabetes mellitus, hypertension, dyslipidemia, family history of CAD, active smoking, D-dimer, and statin treatment